aTyr Pharma
Update in progressATYR (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
aTyr Pharma is a clinical-stage biotechnology company focused on translating tRNA synthetase biology into therapies for fibrosis and inflammation in the United States. Its lead candidate, efzofitimod, is a selective NRP2 modulator in Phase 3 for pulmonary sarcoidosis and Phase 2 trials for sarcoidosis with systemic sclerosis–associated ILD and other ILDs. It also develops ATYR0101 (preclinical) and ATYR0750 (liver disorders). In Japan it collaborates with Kyorin Pharmaceutical. Founded 2005, San Diego.
Company score
- Sentiment
- -0.28
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.13
- Governance
- -0.31
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!